Cratageus monogyna (Hawthorn)

Crataegus monogyna (Hawthorn) is a thorny shrub whose standardized leaf and flower extracts contain oligomeric proanthocyanidins (OPCs) and vitexin rhamnoside as primary bioactives. These compounds inhibit phosphodiesterase and ACE activity while enhancing coronary and peripheral vasodilation, supporting cardiovascular function.

Origin & History

Crataegus monogyna (Hawthorn) is a deciduous shrub or small tree native to Europe, northwest Africa, and western Asia, belonging to the Rosaceae family. It is sourced from the leaves, flowers, berries, and seeds of the plant, with extracts typically prepared using water, ethanol, or phenolic extraction methods to isolate bioactive flavonoids and other polyphenols. As a WHO/EMA monograph plant, it contains standardized levels of flavonoids like quercetin and procyanidins recognized for cardiovascular applications.

Historical & Cultural Context

Hawthorn has been used in European traditional medicine since ancient Greece and Rome, formalized in 16th-19th century herbalism for cardiovascular disorders including angina, hypertension, and heart failure. It was also employed as a mild sedative for stress and sleep disorders, with WHO/EMA monographs now endorsing its use for mild heart failure (NYHA I-II).

Health Benefits

• Reduces blood pressure: Meta-analysis of 8 RCTs showed reductions of 4-5 mmHg systolic and 3 mmHg diastolic blood pressure (moderate evidence)
• Improves heart failure symptoms: Multiple RCTs (n=100-300) demonstrated improved exercise tolerance and ejection fraction in NYHA class II-III patients (moderate evidence)
• Enhances sleep quality: One RCT reported improved sleep alongside blood pressure reduction with 250 mg twice daily (preliminary evidence)
• Supports cardiovascular function: Provides positive inotropic effects and coronary vasodilation based on traditional use and mechanistic studies (traditional evidence)
• May modulate immune function: Animal studies showed increased T/B lymphocyte subsets, though human data lacking (preliminary evidence)

How It Works

Hawthorn's oligomeric proanthocyanidins (OPCs) and flavonoids, particularly vitexin-2-rhamnoside, inhibit phosphodiesterase III and IV, increasing intracellular cAMP and improving myocardial contractility. These compounds also inhibit angiotensin-converting enzyme (ACE), reducing peripheral vascular resistance and lowering blood pressure. Additionally, hawthorn polyphenols upregulate endothelial nitric oxide synthase (eNOS), promoting vasodilation and improving coronary blood flow.

Scientific Research

A meta-analysis of 8 randomized placebo-controlled trials (n>500 total) demonstrated hawthorn's significant effects on hypertension, reducing systolic blood pressure by 4-5 mmHg and diastolic by 3 mmHg over 10 weeks to 6 months. Additional meta-analyses cite RCTs for adjunctive use in left ventricular dysfunction (PMID 12597258), showing standardized extracts improved exercise tolerance and ejection fraction over 8-16 weeks. A recent safety analysis (PMID 39598401) reviewing 37 clinical studies confirmed minimal adverse events.

Clinical Summary

A meta-analysis of 8 randomized controlled trials demonstrated that standardized hawthorn extract (WS 1442 or LI 132) reduced systolic blood pressure by 4-5 mmHg and diastolic by approximately 3 mmHg compared to placebo. Multiple RCTs involving 100-300 participants with NYHA class II-III heart failure showed improved exercise tolerance and ejection fraction with doses of 450-900 mg/day of WS 1442. The large SPICE trial (n=2,681) found no mortality benefit over 24 months in patients with reduced ejection fraction, though a post-hoc subgroup with ejection fractions above 25% showed possible benefit. Overall evidence is moderate for symptomatic heart failure and mild-to-moderate hypertension, with most studies using proprietary standardized extracts rather than raw herb.

Nutritional Profile

Hawthorn (Crataegus monogyna) is primarily consumed as a berry, leaf, or flower extract rather than as a macronutrient food source. **Bioactive compounds (primary pharmacological relevance):** • **Oligomeric proanthocyanidins (OPCs):** 1–3% in berries, 2–6% in leaves/flowers; key cardioactive constituents including procyanidin B2 and epicatechin oligomers. Standardized extracts (e.g., WS 1442) are typically standardized to 18.75% OPCs. • **Flavonoids:** 1–2.5% in berries, up to 4% in leaves/flowers; major compounds include hyperoside (quercetin-3-O-galactoside, ~0.5–1.2%), vitexin (apigenin-8-C-glucoside, ~0.2–0.8%), vitexin-2″-O-rhamnoside (~0.3–1.0%), rutin (~0.1–0.4%), and quercetin glycosides. • **Triterpenic acids:** Ursolic acid (~0.2–0.5%) and oleanolic acid (~0.1–0.3%) in berries. • **Phenolic acids:** Chlorogenic acid (~0.3–0.8%), caffeic acid, and ferulic acid. **Macronutrient profile of fresh berries (per 100 g):** • Carbohydrates: ~15–20 g (predominantly sugars: fructose, glucose, sorbitol ~2–4 g). • Dietary fiber: ~5–8 g (significant pectin content ~2–4 g). • Protein: ~1–2 g. • Fat: ~0.5–1 g. • Calories: ~60–90 kcal. **Micronutrients (per 100 g fresh berries):** • Vitamin C: ~15–100 mg (varies widely by cultivar and ripeness; some reports up to 150 mg). • Vitamin A (as carotenoids, primarily β-carotene): ~0.5–2 mg. • Potassium: ~150–300 mg. • Calcium: ~30–50 mg. • Magnesium: ~15–25 mg. • Iron: ~0.5–1.5 mg. • Phosphorus: ~20–40 mg. **Bioavailability notes:** OPC bioavailability is relatively low (estimated 5–10% absorption of intact oligomers); monomers and dimers are better absorbed than higher-order polymers. Flavonoid glycosides such as hyperoside undergo hydrolysis to aglycones (quercetin) in the gut, with quercetin bioavailability ~2–5%. Vitexin (C-glycoside) is more resistant to hydrolysis and relies partly on colonic microbial metabolism. Standardized extracts (WS 1442 at 900 mg/day or LI 132 at 600 mg/day) deliver clinically relevant doses of OPCs (~170–340 mg) and flavonoids (~50–100 mg). Co-administration with food may modestly improve flavonoid absorption.

Preparation & Dosage

Clinically studied doses for hypertension: 250-500 mg/day of standardized extract (250 mg capsules twice daily). For heart failure adjunctive therapy: 160-1800 mg/day of standardized leaf/flower extracts (standardized to 18.75% oligomeric procyanidins or 2.2% flavonoids) over 8-24 weeks. Maximum studied duration is 6 months. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Coenzyme Q10, Magnesium, Garlic extract, Omega-3 fatty acids, L-Arginine

Safety & Interactions

Hawthorn is generally well tolerated; reported side effects include mild nausea, dizziness, and gastrointestinal upset at doses above 900 mg/day. Clinically significant drug interactions include potentiation of digoxin and other positive inotropes, as well as additive hypotensive effects with antihypertensive medications including ACE inhibitors and beta-blockers. Hawthorn may enhance the vasodilatory effects of nitrates and PDE5 inhibitors such as sildenafil, increasing hypotension risk. Safety in pregnancy and lactation has not been established, and use is not recommended in these populations per WHO monograph guidance.